RT Journal Article
T1 Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience.
A1 Del Campo, José A
A1 Parra-Sánchez, Manuel
A1 Figueruela, Blanca
A1 García-Rey, Silvia
A1 Quer, Josep
A1 Gregori, Josep
A1 Bernal, Samuel
A1 Grande, Lourdes
A1 Palomares, José C
A1 Romero-Gómez, Manuel
K1 Deep sequencing
K1 Direct-acting antivirals
K1 HCV
K1 Mixed infection
K1 NGS
AB The effectiveness of the new generation of hepatitis C treatments named direct-acting antiviral agents (DAAs) depends on the genotype, subtype, and resistance-associated substitutions present in individual patients. The aim of this study was to evaluate a massive sequencing platform for the analysis of genotypes and subtypes of hepatitis C virus (HCV) in order to optimize therapy. A total of 84 patients with hepatitis C were analyzed. The routine genotyping methodology for HCV used at the study institution (Versant HCV Assay, LiPA) was compared with a deep sequencing platform (454/GS-Junior and Illumina MiSeq). The mean viral load in these HCV patients was 6.89×106±7.02×105. Viral genotypes analyzed by LiPA were distributed as follows: 26% genotype 1a (22/84), 55% genotype 1b (46/84), 1% genotype 1 (1/84), 2.5% genotype 3 (2/84), 6% genotype 3a (5/84), 6% genotype 4a/c/d (5/84). When analyzed by deep sequencing, the samples were distributed as follows: 27% genotype 1a (23/84), 56% genotype 1b (47/84), 8% genotype 3a (7/84), 5% genotype 4d (4/84), 2.5% genotype 4f (2/84). Six of the 84 patients (7%) were infected with more than one subtype. Among these, 33% (2/6) failed DAA-based triple therapy. The detection of mixed infection could explain some treatment failures. Accurate determination of viral genotypes and subtypes would allow optimal patient management and improve the effectiveness of DAA therapy.
YR 2017
FD 2017-12-15
LK http://hdl.handle.net/10668/11923
UL http://hdl.handle.net/10668/11923
LA en
DS RISalud
RD Apr 6, 2025